Remove Biosimilars Remove Drug Development Remove Process Improvement
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics. Branded drugs, developed through extensive research and clinical trials, often enjoy patent protection for a limited period.

article thumbnail

Single-use technology propelling upstream bioprocessing market expansion

European Pharmaceutical Review

Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

CMS should draw on lessons from previous transitions, including biosimilar coverage rollouts and site-of-care policy shifts, to avoid known implementation pitfalls. Food and Drug Administration, FDA Patient-Focused Drug Development Guidance Series , March 21, 2025. 15 Inflation Reduction Act of 2022 , Pub. 1818 (2022).

article thumbnail

The next frontier: Global leadership in biopharma

Express Pharma

Sasmitha Sahu, Managing Consultant, GlobalData states, “While India has demonstrated success in generic drug production, the same is not true for novel and biosimilar biopharma products.” ” Embrace technology to transform: Experts and observers also believe that technology will be the true game-changer.